However, due to the limited transportation efficiency of antibodies, in comparison with constant and high production VEGF from tumor cells, and the activation of alternative VEGF downstream signaling, these agents only achieve limited clinical benefits 36,37. The gene discussed is VEGFA; the disease is neoplasm.